Our top pick for
Building a portfolio
Anixa Biosciences, Inc is a diagnostics & research business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Anixa Biosciences employs 7 staff and has a market cap (total outstanding shares value) of USD$67.8 million.
|Latest market close||USD$2.79|
|52-week range||USD$1.33 - USD$4.13|
|50-day moving average||USD$2.5512|
|200-day moving average||USD$2.5191|
|Wall St. target price||USD$8.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.766|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-36.30%|
|1 month (2020-12-24)||-2.11%|
|3 months (2020-10-22)||16.74%|
|6 months (2020-07-22)||-8.52%|
|1 year (2020-01-22)||-31.28%|
|2 years (2019-01-22)||-36.45%|
|3 years (2018-01-22)||4.65|
|5 years (2016-01-22)||2.57%|
|Gross profit TTM||USD$83,750|
|Return on assets TTM||-74.88%|
|Return on equity TTM||-147.19%|
|Market capitalisation||USD$67.8 million|
TTM: trailing 12 months
There are currently 721,709 Anixa Biosciences shares held short by investors – that's known as Anixa Biosciences's "short interest". This figure is 21.3% down from 916,540 last month.
There are a few different ways that this level of interest in shorting Anixa Biosciences shares can be evaluated.
Anixa Biosciences's "short interest ratio" (SIR) is the quantity of Anixa Biosciences shares currently shorted divided by the average quantity of Anixa Biosciences shares traded daily (recently around 1.1 million). Anixa Biosciences's SIR currently stands at 0.63. In other words for every 100,000 Anixa Biosciences shares traded daily on the market, roughly 630 shares are currently held short.
However Anixa Biosciences's short interest can also be evaluated against the total number of Anixa Biosciences shares, or, against the total number of tradable Anixa Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anixa Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Anixa Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0344% of the tradable shares (for every 100,000 tradable Anixa Biosciences shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anixa Biosciences.
Find out more about how you can short Anixa Biosciences stock.
We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.
Anixa Biosciences's shares were split on 18 October 2016.
Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $1.33 up to $4.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 1.5633. This would suggest that Anixa Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.